AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021

July 22, 2021 | Last Trade: US$4.03 0.23 5.92

AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

The live webcast of the earnings conference call will be available through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more info, visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Stock Quote

Last Trade:	US$4.03
Daily Change:	0.23 5.92
Daily Volume:	7,273,667
Market Cap:	US$1.190B

May 30, 2025 AbCellera Biologics Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 May 14, 2025 AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause May 12, 2025 AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit May 09, 2025 AbCellera Biologics Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting May 08, 2025 AbCellera Reports Q1 2025 Business Results LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE